Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03309111 · ClinicalTrials.gov registry record · Phase 1
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma
A Phase 1 study, sponsored by Ichnos Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
NCT03309111 is a Phase 1 study that has completed, run by Ichnos Sciences. The registered enrollment target is 81 participants.
The verdict
NCT03309111, a Phase 1 study, has completed, sponsored by Ichnos Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
Study Summary
The purpose of this study is to assess safety, efficacy, pharmacokinetic (PK)/pharmacodynamic (PD), and immunogenicity with ISB 1342 in subjects with relapsed/refractory multiple myeloma.
Interventions
- BIOLOGICAL ISB 1342
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2017-10-25 |
| Est. Completion | 2023-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03309111
The ClinicalTrials.gov registry entry for NCT03309111 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ichnos Sciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ISB 1342 is the first listed.
NCT03309111 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03309111 about?
NCT03309111 is a clinical study titled "Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma". The purpose of this study is to assess safety, efficacy, pharmacokinetic (PK)/pharmacodynamic (PD), and immunogenicity with ISB 1342 in subjects with relapsed/refractory multiple myeloma.
What is the current status of trial NCT03309111?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2017-10-25. Estimated completion is 2023-12-15.
What interventions are being tested in trial NCT03309111?
The interventions under investigation include: ISB 1342 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03309111?
This trial is sponsored by Ichnos Sciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.